Ornidazole

Bezeichnung:Ornidazole

CAS-Nr16773-42-5

Englisch Name:Ornidazole

CBNumberCB5735895

SummenformelC7H10ClN3O3

Molgewicht219.63

MOL-Datei16773-42-5.mol

Ornidazole physikalisch-chemischer Eigenschaften

Schmelzpunkt	85-90°C
Siedepunkt	443.2±40.0 °C(Predicted)
Dichte	1.6545 (rough estimate)
Brechungsindex	1.6000 (estimate)
storage temp.	Sealed in dry,Room Temperature
Löslichkeit	Soluble in ethanol at 50mg/ml
pka	2.4 ± 0.1(at 25℃)
Aggregatzustand	Solid
Farbe	Crystals from toluene
maximale Wellenlänge (λmax)	276nm(H2SO4 aq.)(lit.)
Merck	14,6872
InChIKey	IPWKIXLWTCNBKN-UHFFFAOYSA-N
CAS Datenbank	16773-42-5(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xn
R-Sätze:	22
S-Sätze:	36
WGK Germany	3
RTECS-Nr.	NI5460000
HS Code	2933.29.4300
HazardClass	IRRITANT
Toxizität	LD50 in rats, mice (mg/kg): 1780, 1420 orally (Grunberg); LD50 in mice (mg/kg): >2000 orally, >2000 i.p. (Hoffer, Grunberg)

Gefahreninformationscode (GHS)

Ornidazole Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R22:Gesundheitsschädlich beim Verschlucken.
S-Sätze Betriebsanweisung:
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
Beschreibung
Ornidazole is an orally bioavailable 5-nitroimidazole derivative with antibacterial and antiprotozoal activities. Ornidazole inhibits the growth of clinical isolates of B. fragilis (MICs = 0.5-5 μM) and various anaerobic bacteria when used at concentrations ranging from less than 0.1 to 3.2 μg/ml. It also inhibits the growth of Giardia isolates (IC₅₀s = 0.01-0.47 μg/ml). Oral administration of ornidazole reduces T. vaginalis and T. foetus infection in mice and E. histolytica infection in rats with curative dose (CD₅₀) values of 37, 3, and 10 mg/kg, respectively. Ornidazole (400 mg/kg per day) induces infertility in male rats within 7 days and inhibits spermatozoa binding to rat oocyte zona pellucida.
Chemische Eigenschaften
Crystalline Solid
Originator
Tiberal,Roche,W. Germany ,1977
Verwenden
Ornidazole is a drug that cures some protozoan infections. It has been investigated for use in Crohn's disease after bowel resection. It is indicated in treatment of mixed amoebiasis, mixed amoebic dysentery, mixed giardiasis, trichomoniasis, bacterial vaginosis, Sexually transmitted diseases, infections of gynaecology, lower respiratory tract infections, ENT, surgical and dental infections.
Verwenden
estrogen
Verwenden
Anti-infective
Definition
ChEBI: A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.
Manufacturing Process
5g of 1-(2,3-epoxypropyl)-2-methyl-5-nitroimidazole was added to 30 ml of concentrated aqueous hydrochloric acid. The solution was heated to the boiling point for 20 minutes, chilled, diluted with 30 ml of water and carefully neutralized with ammonia to a pH of 7 to 8. It was then saturated with ammonium sulfate. The precipitated oil crystallized after several days. Recrystallized from toluene, there was obtained the 1-(3-chloro-2hydroxypropyl)-2-methyl-5-nitroimidazole product melting at 77°C to 78°C.
Therapeutic Function
Antiinfective
Pharmazeutische Anwendungen
A 5-nitroimidazole available for oral administration, intravenous infusion and as a vaginal pessary. Its activity closely parallels that of metronidazole and tinidazole.
Peak plasma levels after a single 750 mg or 1.5 g oral dose reach 11 mg/L and 30 mg/L, respectively, within about 2 h. The half-life is 12–14 h. It is well absorbed from the vagina, with peak plasma concentrations of 5 mg/L being reached 12 h after the insertion of a 500 mg vaginal pessary. After a single 1 g intravenous infusion for colorectal surgery, serum levels reached about 24 mg/L after 15 min and about 6 mg/L after 24 h. It has wide tissue distribution, including CSF. Plasma protein binding is 10–15%.
It is metabolized in the liver, mainly to hydroxymethyl derivatives. The plasma clearance rate decreases in hepatic failure because of reduced liver metabolism and decreased biliary elimination. About 60% of an oral dose is recovered in the urine and 20% in the feces. The dosing interval should be doubled in patients with severe hepatic impairment, but it is unnecessary to reduce the dose in patients with impaired renal function. It is removed by hemodialysis.
Toxicity and side effects are similar to those of metronidazole and tinidazole and it has similar clinical uses. It has been shown to be effective for the prevention of recurrence of Crohn’s disease after ileocolonic resection.
Sicherheitsprofil
Poison by intravenous route. Moderately toxic by ingestion and intraperitoneal routes. Experimental reproductive effects. Mutation data reported. Whenheated to decomposition it emits very toxic fumes of Clí and NOx.

Ornidazole Upstream-Materialien And Downstream Produkte

Ornidazole Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

16773-42-5, Ornidazole Verwandte Suche:

Send Inquriy